Jyong Biotech (MENS) vs PepGen (PEPG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PepGen (PEPG) has outperformed Jyong Biotech (MENS) over the past year, losing 51.1% versus a loss of 95.9%. PepGen is the larger company by market cap ($164.6 million vs $159.7 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MENS | PEPG |
|---|---|---|
| Share price | $2.10 | $2.38 |
| Market cap | $159.66M | $164.62M |
| 1-day change | +2.44% | -0.83% |
| YTD return | -46.84% | -63.44% |
| 1-year return | -95.89% | -51.13% |
| EPS (TTM) | $-0.06 | $-1.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $63.00 | $7.80 |
| 52-week low | $1.43 | $1.31 |
| Distance from 52-week high | -96.67% | -69.49% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +328.15% |
| Average volume | 45.62K | 946.80K |
| Shares outstanding | 74.23M | 69.17M |
| Employees | 27 | 57 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PEPG has outperformed MENS by 44.8 percentage points over the past year.
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About PepGen
PEPG stock →PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
MENS vs PEPG FAQ
Which is bigger, Jyong Biotech or PepGen?
PepGen (PEPG) is larger, with a market capitalization of $164.62M compared with $159.66M for Jyong Biotech (MENS).
Which stock has performed better over the past year, MENS or PEPG?
PEPG returned -51.13% over the past 12 months, compared with -95.89% for MENS (price return, excluding dividends). Past performance does not predict future results.
Are Jyong Biotech and PepGen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.